In next-gen IO race in NSCLC, BioNTech/BMS and Pfizer are divided on overall survival approach Read more
ASCO: Gilead touts ADC ovarian cancer data as proof Tubulis buyout was ‘a good deal’ Read more
Legend scientific founder returns to ASCO with new ambition for high-yield, non-gene-editing CAR-T platform Read more
